Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Bahrain Pharmaceuticals And Healthcare
Industry SWOT — 6
Bahrain Political
SWOT — 7
Bahrain Economic SWOT — 8
Bahrain Business Environment SWOT — 9
Pharmaceutical
Business Environment Ratings — 10
Table: Middle East And
Africa Pharmaceutical Business Environment Ratings for
Q309 — 10
Limits of Potential
Returns — 11
Risks to Realisation of
Returns — 11
Bahrain – Market
Summary — 13
Regulatory Regime — 14
Recent Regulatory Developments — 14
GCC Healthcare
Collaboration — 15
Intellectual Property
Developments — 17
Pricing and Reimbursement
Regime — 17
Regional Price
Harmonisation — 18
Free Trade Agreement with the
US — 19
Other Free Trade
Agreements — 20
Industry
Developments — 22
Epidemiology — 22
Table: Leading Causes Of Death In Bahrain, 2002 — 24
HIV/AIDS — 24
Healthcare Sector — 24
Primary, Secondary and Tertiary Healthcare — 25
Health
Insurance — 26
Table: National Health Insurance Scheme
Breakdown — 27
Strategic Healthcare
Goals — 29
Healthcare Sector
Investment — 30
Features Of Dilmunia Health
Island — 31
Pharmaceutical Sector — 31
Pharmaceutical Retail — 32
Research and
Development — 33
International
Collaboration — 33
Medical
Devices — 35
Industry Forecast
Scenario — 37
Overall Market
Forecast — 37
Table: Bahrain - Drug Expenditure
Indicators, Historical Data and Forecasts — 38
Key Growth
Factors – Industry — 39
Table: Bahrain - Health
Expenditure Indicators, Historical Data and Forecasts — 40
Key Growth Factors – Macroeconomic — 41
Table:
Bahrain - Economic Activity, 2005-2013 — 43
Prescription
Market Forecast — 44
Table: Bahrain – Prescription
Market Indicators, Historical Data and Forecasts (BHDmn unless otherwise
indicated) — 45
Patented Market
Forecast — 46
Table: Bahrain - Prescription Drug Market
Indicators, Historical Data and Forecasts — 46
Generics
Drug Market Forecast — 47
Table: Bahrain - Generics Drug
Market Indicators, Historical Data and Forecasts — 48
OTC
Market Forecast — 49
Table: Bahrain - OTC Market
Indicators, Historical Data and Forecasts (BHDmn unless otherwise
stated) — 50
Pharmaceutical Trade
Forecast — 51
Table: Bahrain - Pharmaceutical Trade
Balance Indicators, Historical Data and Forecasts
(US$mn) — 52
Medical Devices — 53
Table: Bahrain - Medical Device Market Indicators, Historical Data and
Forecasts — 54
Other Healthcare Data
Forecasts — 55
Table: Bahrain - Other Health Indicators,
Historical Data and Forecasts, 2003-2013 — 55
Key Risks to
BMI’s Forecast Scenario — 56
Competitive
Landscape — 57
Company Monitor — 58
Multinational Companies — 58
Novartis — 58
Johnson & Johnson — 60
Merck & Co — 62
Pfizer — 64
GlaxoSmithKline — 65
GlaxoSmithKline — 66
Indigenous
Companies — 67
Bahrain Industrial Pharmaceutical Co
(Bidapharm) — 67
Al-Jishi
Corporation — 68
Behzad Medical
Establishment — 69
Yousuf Mahmood Husain
Company — 70
Country Snapshot: Bahrain Demographic
Data — 71
Section 1: Population — 71
Table: Demographic Indicators, 2005-2030 — 71
Table:
Rural/Urban Breakdown, 2005-2030 — 72
Section 2: Education
and Healthcare — 72
Table:
Education — 72
Table: Vital Statistics,
2005-2030 — 72
Section 3: Labour Market and Spending
Power — 73
Table: Employment
Indicators — 73
Table: Consumer Expenditure, 1999-2004
(US$) — 73
Table: Average Annual
Wages — 73
BMI Forecast Modelling — 74
How We Generate Our Pharmaceutical Industry Forecasts — 74
Pharmaceutical Business Environment Ratings
Methodology — 75
Ratings Overview — 75
Table: Pharmaceutical Business Environment Indicators — 76
Weighting — 77
Table: Weighting Of
Components — 77
Sources — 77
| 
View Cart
